Organon & Co.

As of September 19, 2025, Organon & Co. is in a mildly bearish trend, indicated by daily moving averages and bearish signals from the monthly MACD and KST, while underperforming the S&P 500 with a return of -45.77% compared to its 16.64%.

As of September 19, 2025, Organon & Co. shows a mildly bearish trend with mixed technical signals, underperforming the S&P 500 significantly with a year-to-date return of -29.96% compared to the index's 13.31%.

As of July 24, 2025, Organon & Co. shows a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 recently but underperformed over the longer term.

As of May 2, 2024, Organon & Co. is considered very attractive for investment due to its undervaluation, reflected in a P/E ratio of 3 and an EV to EBITDA ratio of 6.41, despite a year-to-date return of -27.28%.

As of May 2, 2024, Organon & Co. is considered very attractive due to its undervalued status with a P/E ratio of 3, an EV to EBITDA of 6.41, and a high ROE of 163.16%, despite a 52.98% decline in stock performance over the past year compared to the S&P 500's 10.26% increase.

As of March 27, 2025, the technical trend for Organon & Co. has shifted to a bearish stance, supported by bearish daily moving averages and KST indicators, despite mixed signals from the MACD.

Organon & Co. is a small-cap pharmaceutical and biotechnology company with recent net sales of $1.513 billion and a net profit of $87 million. Key metrics include a P/E ratio of 3.00, a dividend yield of 0.20%, and a market cap of $2.56 billion.

As of Jun 18, Organon & Co. has a market capitalization of 2,560.57 million, with net sales of 6,294.00 million and a net profit of 750.00 million over the latest four quarters.